In selected groups of patients with atrial fibrillation, ablation can lead to an improvement in symptoms and/or prognosis. To avoid complications, anticoagulation before, during and after ablation should be criteria-driven. There is a consensus that periprocedural oral anticoagulation (OAC) is generally recommended regardless of the thromboembolic risk. On the other hand, the longer-term continuation of OAC is controversial. The ALONE-AF study published in 2025 has provided new evidence in this regard.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
Related Topics
You May Also Like
- Irritable Bowel Syndrome
Functional disorder of gut-brain interaction – a biopsychosocial concept
- GLP1 receptor agonists
Positive influence on substance use and addiction
- Sleep apnea and cardiovascular diseases
Breathless through the night
- Diagnostics, differentiation and multimodal therapy
Vulvar diseases and vulvodynia
- From symptom to diagnosis
Abdominal pain – Prostate lipoma
- Acute pulmonary embolism: new AHA/ACC guideline
Practical recommendations for risk-stratified triage
- Why lipoprotein(a) is the biggest therapeutic vacuum in cardiology
Lp(a): The underestimated risk factor before the turning point
- Modern system therapeutics for hidradenitis suppurativa